It has been reported that glucagon-like peptide-1 (GLP-1) agents have been associated with both the increased risk of cancer and inhibition of tumor growth and metastases. The aim of this study is to evaluate the effect of liraglutide on hepatocellular carcinoma cells -HepG2. Cytometry was used to evaluate mechanism related to decreased cell proliferation. Nuclear staining and morphometric analysis were also used to verify the process that was taking place after treatment with liraglutide, and in order to better understand the mechanism, TGF-β1 was performed. HepG2 cells decreased proliferation after liraglutide treatment without altering oxidative stress levels. Liraglutide was able to induce autophagy and senescence through the increase of TGF-β1 which possibly explains the growth decrease. We have demonstrated that liraglutide has an antiproliferative effect in HepG2 cells inducing autophagy and senescence by the increase of TGF-β1.
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Introduction
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer (Lozano et al., 2012) . Globally, is the fifth most common cancer in men and the seventh most common in women, and accounts for at least 700.000 deaths worldwide annually (El-Serag, 2011) . There is currently no curative therapy for the HCC, especially for tumors that not respond to chemotherapy, mainly due to the high level of intrinsic and acquired chemo-resistances. Thus, the development of novel and effective therapeutic approaches for this devastating disease is of utmost relevance (Yang and Roberts, 2010) .
Epidemiological evidence has shown that some antidiabetic drugs may be associated with the risk of developing cancer. Drugs that increase insulin levels can result in weight gain increasing the risk of cancer, on the other hand, drugs that reduce insulin levels are associated with weight loss and seem to have a protective effect against cancer (Onitilo et al., 2012) . In recent years, incretin based therapies have been the optimal treatment options for type 2 diabetes mellitus (T2DM). The incretin hormone glucagon-like peptide-1 (GLP-1), which is released from intestinal L cells of the small intestine which targets pancreatic β-cells to release insulin and reduce glucagon production in response to food intake (Brubaker, 2006) . The short circulating half-life (less than 2 min) of GLP-1 limits its potential use.
Liraglutide is a long-acting GLP-1 receptor (GLP-1R) agonist that shares a 97% amino acid sequence identify with human GLP-1 and displays a much longer half-life of about 13 h (Jacobsen et al., 2009 ). In 2010, was approved by the US FDA to type 2 diabetes mellitus (Drucker et al., 2010) , through the stimulation of insulin secretions and improve pancreatic islet function (Eng et al., 2014) .
Some reports have shown that GLP-1 based agents are associated with an increased risk of pancreatitis and pancreatic cancer (Butler et al., 2013; Elashoff et al., 2011) , while others have found no such effects (Tatarkiewicz et al., 2013; Vrang et al., 2012) . Other studies have shown that GLP-1-based agents are associated with autophagy induction (Jalewa et al., 2016; Li et al., 2016) and inhibition of tumourigenicity and metastasis in human pancreatic cancer cells via PI3K/AKT pathway (Zhao et al., 2014a) . Over the last few years a connection between autophagy and the development of senescence has been established (Young and Narita, 2010) . This connection reinforces the role of autophagy in the suppression of tumourigenesis and may be an additional mechanism of this suppression.
GLP-1R expression in hepatocytes remains controversial. Gupta et al. demonstrated that GLP-1 receptors are present on human hepatocytes and the exposure of hepatocytes to GLP-1 receptors agonists led to a reduction of fat load in cell lines (Gupta et al., 2010) . In contrast, other investigators have failed to detect mRNA transcripts encoding a full-length GLP-1R in human, rat, or mouse liver (Flock et al., 2007; Tomas et al., 2010) . The aim of this study was to evaluate whether Liraglutide can inhibit HepG2 cells proliferation and what is their relationship amongst signaling pathways such autophagy, apoptosis and senescence.
Materials and methods

Cells and treatment
Human hepatocellular carcinoma HepG2 cell line and the murine HSC cell line, GRX, were obtained from Rio de Janeiro Cell bank (Federal University, Rio de Janeiro, Brazil). Cells were maintained in DMEM, supplemented with 10% FBS, and 1% penicillin (100 units/ml) and streptomycin (100 µg/ml) 2 g/l 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) buffer and 3,7 g/l NaHCO3 in humidified atmosphere of 5% CO2 at 37°C.
Liraglutide was dissolved in DMEM with 10% SFB, at concentrations of 5, 10, 15 and 20 µM. HepG2 cells were incubated and the analyses were performed 24 and 48 h after treatment. All experiments were done five times.
Cell proliferation
HepG2 cells were seeded into 96-well plates at a density of 2,5×10 4 cells per well and treated with different concentration of Liraglutide. For determination of cell number, cells were counted with a Neubauer chamber. The cellular proliferation was performed by trypan blue dye exclusion. Briefly, cells were treated for 24 or 48 h with different concentrations (0, 5, 10, 15, 20 μM) of Liraglutide. Control (C) wells contained medium and FBS 10%. Three replicate wells were used at each concentration tested, including control. The number of viable cells was determined by mixing 25 μL of cell suspension and 25 μL of 0,4% trypan blue stain solution (Sigma-Aldrich, USA), using a hemocytometer under a light microscope (Nikon Optiphot, Japan). Blue cells were counted as dead cells. Since the greatest inhibition was seen after 48 h treatment with 15 and 20 µM of Liraglutide, we selected these doses for further experiments.
Measurement of lactate dehydrogenase
LDH assay was used to assess the cytotoxicity of treatment in HepG2 cells, since leakage of the LDH (cytoplasmic located enzyme) into the extracellular medium is evidence of membrane disruption. Cells were seeded and treated with the selected dose for 48 h as described for the Trypan blue exclusion assay. Enzyme activity was measured in both supernatants and the cell lysate using colorimetric assay Lactate Desidrogenase kit (Labtest, Brazil) . For the control of cell lysis, DMEM with 5% Tween solution was used. The amount of LDH was calculated by measuring the absorbance at 492 nm using ELISA microplate reader. The sum of the amount of LDH in the supernatant and in the cell lysate was considered as 100% of the enzyme content. Then, we calculated the percentage released (i.e. present in the supernatant) based on the total enzyme content.
DCFH-DA
The generation of intracellular reactive oxygen species (ROS) of HepG2 cells was evaluated based on the intracellular peroxide-dependent oxidant of 2′, 7′-dichlorodihydrofluorescein diacetate (DCFH-DA), which forms a fluorescent compound, 2′, 7′-dichlorofluorescein (DCF). Firstly, the cells were seeded into 96-well plates at a density of 2,5×10 4 cells per well and treated with 15 µM and 20 µM of Liraglutide, and for positive control 100 µM and 1000 µM of H 2 O 2 . Cells were collected by trypsinization, washed twice with PBS and then incubated with 200 μL/well of phosphate buffer containing 10 µM of DCFH-DA at 37°C for 30 min. The fluorescence intensity was monitored with a VICTOR® microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 520 nm.
Thiobarbituric acid reative substances
To determine the thiobarbiture acid reative substances (TBARS) concentrations, the cell lysate was used. HepG2 cells were seeded into 96-well plates at a density of 2,5×10 4 cells per well and treated with 15 µM and 20 µM of Liraglutide. The compound resulting from the reaction of the thiobarbituric acid and malondialdehyde was measured at 535 nm. The result has been adjusted according to the protein concentration of each sample and is presented in nM / mg protein.
Catalase
Catalase activity was measured in the cell lysate obtained from the cell culture using specific reagent and measuring the H 2 O 2 decrease after 1 min. HepG2 cells were seeded into 96-well plates at a density of 2,5×10 4 cells per well and treated with 15 µM and 20 µM of Liraglutide. The result was corrected by the protein concentration of each sample and the final value is presented in UCAT/mg protein.
GSH
The GSH concentration was performed by the method recommended by Beutler et al. (1963) in the lysate obtained from the cell culture using specific reagent. HepG2 cells were seeded into 96-well plates at a density of 2,5×10 4 cells per well and treated with 15 µM and 20 µM of Liraglutide. It was measured in spectrophotometry at 412 nm and the concentration of GSH was expressed in optical density/ 1000cells.
Acridine orange
Formation of acidic vesicular organelles (AVO's), a morphological characteristic of autophagy, was quantitated by acridine orange staining where the cytoplasm and nucleolus fluoresce green and orange, whereas acidic compartments fluorescence orange. The intensity of orange fluorescence is proportional to the degree of acidity. Therefore, the volume of cellular acidic compartment can be quantified (Paglin et al., 2001) . Briefly, the cells were seeded into 96-well plates at a density of 2, 
Apoptosis assay by Annexin V-FITC and PI staining
Annexin V Fluorescein (FITC) and Propidium Iodide (PI) double staining assay (Santa Cruz Biotechnology, USA) was performed to quantify apoptosis using FACScan flow cytometer (BectonDickinson, USA). Cells were seeded into 96-well plates at a density of 2,5×10 4 cells per well, after 48 h of treatments, cells were harvested, washed with ice-cold PBS, ressuspended in 300 μL of binding buffer (10 mM Hepes/ NaOH (pH 7,4), 140 mM NaCl, 2,5 mM CaCl2) with a cell density of 1×10 6 cells/ml, incubated with 4 μL of Annexin V FITC and 2 μL of PI, mixed and incubated for 15 min at room temperature in the dark.
After, samples were analyzed by flow cytometry to identify apoptotic cells. Cells without treatment were used as a negative control and cells treated with cisplatin 40 µM were used as positive control. Data were analyzed using FlowJo 7.6.5 software (Tree Star Inc., Ashland OR). Analysis allows discrimination among necrotic cells (Annexin V-/PI+), late apoptotic or necrotic cells (Annexin V+/PI+) and early apoptotic (Annexin V+/PI-).
Nuclear Morphometric Analysis (NMA)
The analysis of the nuclear size and irregularity was performed to further investigate the mechanism of cellular toxicity related to the treatment. Cells were seeded with a cell density of 10×10 3 cells per well in 24-well plates and incubated for 24 h at 37°C in a 5% CO2 incubator. After, cells were treated with 15 µM and 20 µM of Liraglutide, and for positive control 150 µM H 2 O 2. After 48 h incubation, cells were fixed with 4% paraformaldehyde for 2 h. Next, fixed cells were permeabilized with 0.3% 4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol, tOctylphenoxypolyethoxyethanol, Polyethylene glycol tert-octylphenyl ether (triton X-100) in phosphate buffered saline (PBS) for 30 min and subsequently marked with a solution containing 300 nM 40,6-diamidino-2-phenylindole (DAPI) for 2 min. The incubations were performed at room temperature and cells were photographed using a fluorescence microscope of (IX71, Olympus). The analysis of nuclear morphometry was performed using the Image Pro Plus 6.0 software (IPP6 -Media Cybernetics, Silver Spring, MD). The percentages of normal, small and regular, large and regular and irregular nuclei were determined as described by Filippi-Chiela et al. (2012) .
Cell cycle
The cell cycle arrest of HepG2 cells was evaluated by 7-AAD. Firstly, the cells were seeded into 96-well plates at a density of 2,5×10 4 cells per well and treated with 15 µM and 20 µM of Liraglutide, and for positive control 150 µM of H 2 O 2 . Cells were collected by trypsinization, washed twice with PBS and then while vortexing (to losen the pellet) add 2,5 ml/sample of 70% ethanol drop by drop into the cell pellet. Incubate −20°C for 2 h. After, washed twice to remove ethanol, perform the first wash in PBS and the second in Stain Buffer. Centrifuge the cells and aspirate the supernatant, ressuspend the cells in 100 μL of Stain Buffer, add 4 μL of 7-AAD and incubate 15 min at room temperature. After, samples were analyzed by flow cytometry to identify the cell cycle phases. Data were analyzed using FlowJo 7.6.5 software (Tree Star Inc., Ashland OR). Analysis allows discrimination among Sub-G1, Go/G1, S, G2/M.
TGF-β1 quantification
Transforming growth factor beta 1 (TGF-β1) concentration was measured in cell supernatants using a commercially available ELISA kit. The kit contained a specific monoclonal antibody immobilized on a 96-well microtiter plate that bound TGF-β1 in the aliquot and a second enzyme-conjugated specific polyclonal antibody. Following several washings to remove unbound substances and antibodies, a substrate solution was added to the wells. Color development was stopped by sulfuric acid, and optical density was determined at 540 nm with the correction wavelength set at 570 nm in an ELISA plate reader. Results were calculated on a standard curve concentration and multiplied for the dilution factor. TGF-β1 levels were expressed as pg/ml.
Statistics
Data were analyzed by one way analysis of variance (ANOVA) followed by Tukey multiple comparison test using a statistical software package (SPSS for windows, V. 13.0, Chicago, USA). The differences were considered significant when the statistical analyses gives P < 0,05.
Results
Liraglutide inhibits cell proliferation in HepG2 cells, not causing cytotoxicity
To assess the antiproliferative effect of Liraglutide, we incubate HepG2 cells for 24 and 48 h with different concentrations (0, 5, 10, 15, 20 µM). There was no significant change in cell proliferation after 24 h of treatment between groups, however, when incubated for 48 h, 15 µM and 20 µ of Liraglutide caused a significant decrease in cell proliferation compared with control group (Fig. 1A) . This decrease could happen by a cytotoxic effect and, for this reason, we evaluate this phenomenon measured LDH release by cells. In Fig. 1B , it can be seen that the liraglutide was not and, due to these results, our study developed using 15 µM and 20 µM of Liraglutide. In order to verify if another GLP-1 analog could exert the same effect, cells were treated with exenatide (15 µM) where it also showed a decrease in proliferation (Fig. 1C) . In addition, liraglutide was also tested in another cell line, showing a proliferation decrease of GRX cells (Fig. 1D) .
Reactive oxygen species is not involved in Liraglutide-induced antiproliferative effects in HCC cells
We evaluated the DCFH-DA fluorescence and TBARS concentrations in order to investigate the role of reactive oxygen species in Liraglutide -induced antiproliferative effects. Additionally related antioxidant enzymes catalase (CAT) and glutathione reductase (GSH) were used to value antioxidant potential. As shown in Fig. 2A -C, Liraglutide treatment not caused significant difference in oxidative stress generation, as well as in catalase antioxidant enzyme. Notably, Liraglutide treatment increase the GSH concentrations (Fig. 3D) .
Liraglutide induces autophagy
Autophagy occurs constantly and constitutively, at a basal level, in many tissues (Mizushima et al., 2004) . Is a genetically regulated and evolutionarily conserved program characterized by the formation of double membrane cytosolic vesicles, autophagosomes, which sequester cytoplasmic content and deliver it to lysosomes (Mizushima et al., 2008) . We investigate if Liraglutide could induce autophagy in HCC cells. The emission of orange fluorescence was quantified using flow cytometry and found to be 8% higher in liraglutide-treated cells than in untreated cells ( control group) (Fig. 3A-B) , showing that Liraglutide stimulates autophagic vacuoles formation in HCC cells. The Fig. 4C confirms that Liraglutide treatment resulted in accumulation of AVO'S in HepG2 cells. Apoptosis and autophagy are not always separate process, because there may be a relationship between these two pathways. In many cases, inhibition of apoptosis causes autophagy and inhibition of autophagy may trigger apoptosis (Kondo et al., 2005) . So, autophagy can block apoptosis and cells may die by a non-apoptotic mechanism. To investigate this relationship, we performed the apoptosis by flow cytometry, which does not change significantly between groups (Fig. 4) .
Treatment with Liraglutide induced cell cycle arrest and senescence
Senescence is an irreversible cell cycle arrest, mechanism of action of some anticancer drugs. In an attempt to get the antiproliferative mechanism of Liraglutide, we evaluated the senescence by dye DAPI, morphology analysis by NMA and cell cycle by cytometry. In Fig. 5A , we can see that the morphological profile indicated senescence, with an increase of 10% of cells with large and regular nuclei, a morphological feature of senescent cells (Fig. 5B) . To confirm the senescence, we performed the cell cycle analysis by flow cytometry where it was found that Liraglutide produced an accumulation of cells at G 0 /G 1 phase (Fig. 6) , confirming cell cycle arrest.
TGF-β as inducer of autophagy and senescence
Transforming growth factor-β (TGF-β) regulates the growth, differentiation and migration of various types of cells. Similar to the duality of autophagy, TGF-β carries both a tumor promoting functions as suppression (Wakefield and Roberts, 2002) . TGF-β has been reported to induced autophagy in normal bovine mammary epithelial BME-UV1 cells (Gajewska et al., 2005) , hepatocellular carcinoma cells HUH-7 and mammary carcinoma cells MDA-MB-231 (Kiyono et al., 2009 ). Therefore, we assessed the TGF-β concentrations in the supernatant of the cell cultures and demonstrated that Liraglutide significantly increase TGF-β production of HepG2 cells. Fig. 7 .
Rapamycin and liraglutide decreased the stimulation of insulin on cell proliferation
To verify that regulation of cell proliferation by insulin is connected to the modulation of PI3K/Akt/mTOR signaling, we treated HepG2 cells with insulin, rapamycin and liraglutide together. HepG2 cells were treated with insulin (200 nM), rapamycin (200 nM) and liraglutide (15 µM). Fig. 8 .
Discussion
The GLP-1R agonist liraglutide is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (Drucker et al., 2010) . Analyses for data based on the FDA Adverse Event Reporting System reported that exedin-4 (another GLP-1 analog) was associated with elevated risk for pancreatic cancer (Elashoff et al., 2011) , however, some studies have indicated that others GLP-1R agonists had anticancer effect (Koehler et al., 2011; Ligumsky et al., 2012) , including pancreatic cancer where liraglutide was able to inhibit cell proliferation (Zhao et al., 2014b) . Through these results, we can conclude that the liraglutide role in cancer is still controversial.
Nevertheless, the potential of GLP-1 agents to inhibits tumourigenicity in pancreatic cancer cells (He et al., 2016; Koehler et al., 2011; Zhao et al., 2014a) , underscores the importance of investigating these drugs as a possible alternative for cancer treatment. The findings indicated that GLP-1R activation by liraglutide plays an important role in suppressing the growth, migration and invasion and they show that liraglutide can inhibits tumourigenicity and metastasis via inactivation of the PI3K/AKT signaling pathway (Zhao et al., 2014a) . These results corroborate with our findings that Liraglutide can provoke cell proliferation decrease and that this effect is not due to cytotoxicity.
We showed that another GLP-1 analog, exenatide, also has an antiproliferative effect on HepG2 cells. In addition, in order to prove the effect of liraglutide in other liver cells, we used the GRX cell line that under standard culture conditions these cells expressed myofibroblast phenotype, demonstrating that liraglutide is able to inhibit growth in more than one liver cell line.
Oxidative stress has been associated with the etiology of many types of cancer, because reactive oxygen species regulated signaling proteins involved in cell growth, proliferation and differentiation (Mahalingaiah et al., 2016) . The increase of reactive oxygen species can lead to cell transformation and tumorigenesis, then, the decrease of these reactive molecules can became an ally in combating tumor progression. Our results demonstrated that Liraglutide does not decrease the reactive oxygen species production or increases the protection of these cells against these reactive oxygen species, except for GSH levels that significantly enhance. GSH may protect the cell membrane by reducing harmful compounds such reactive oxygen species (Deneke and Fanburg, 1989) . Interventions that increase intracellular GSH levels can improve the cell's detoxification and help reduce the incidence of cancer (Balendiran et al., 2004) . The increase of capacity of GSH, in order to protect cells from redox related changes or environmental toxins, represents a persistent aim in the search for cytoprotective strategies against cancer, on that side, the increased that we found in GSH levels may be beneficial to combat HCC. By this, we conclude that the cell proliferation decrease found after Liraglutide treatment was not caused by reactive oxygen species.
We also evaluated liragltuide's ability to induce autophagy in HCC cells. The autophagy is required to preserve the cell homeostasis through the elimination of unfolded proteins and malfunctioning organelles. In the past decade, several genetic links have emerged between autophagy defects and cancer, providing increasing support for the concept that autophagy is a bona fide tumor suppressor pathway. Inhibition of autophagy provide a rationale target in the anti-cancer therapy because present survival role in tumor cells (Levy and Thorburn, 2011) . That is, autophagy plays bidirectional and paradoxical roles in tumor suppressor and tumor progression (Eisenberg-Lerner and Kimchi, 2009) . Recent studies show that autophagy-induced cell death refers to a non-apoptotic cellular death, with prominent formation of autophagosomes (Pattingre et al., 2005) . Thus, our results that Liraglutide is capable of increasing autophagy are beneficial for tumor suppression.
Knowing that autophagy acts as a kind of intermediate process, and that, after it, the cells must have an endpoint as, for example, apoptotic cell death or senescence, we decided to evaluate their outcomes. When anticancer treatment causes some damages in cells, autophagy stars to degrade those damaged organelles acting as mechanism of death. Unlike apoptosis, in cell death by autophagy no caspase activation or nuclear fragmentation (Kondo et al., 2005) . In our results, observed in annexin-V test, shows no induction of apoptosis by liraglutide. Another mechanism that can be triggered after autophagy is senescence (Young and Narita, 2010) . Cellular senescence refers to the stable state of cell cycle arrest in the G 1 phase in response to stress. The cell cycle is carefully regulated process, essential for proper functioning of a cell, the decision regarding cell division is based on several growth factors and is performed during G1 phase (Blagosklonny and Pardee, 2002) .
Senescent cells adopt an expanded morphology, with flattened cytoplasm and increased granularity. The hypothesis of senescence as a tumoral suppressor has been confirmed in animal models (Donehower et al., 1992; Sharpless et al., 2001) , for example, inducing premature senescence in murine mammary epithelial cells suppresses tumor development (Boulanger and Smith, 2001 ). In our findings Liraglutide was able of induce cell cycle arrest and senescence, showing an important mechanism of cell growth suppression.
The TGF-β1 may induce different cellular response, depending on the context, leading proliferative response through controlling cell behavior, and this became evident in cancer where TGF-β can act as a suppressor or a promoter of tumorigenesis. Kiyono et al. examined the effect of TGF-β on autophagy in HuH7 human hepatocellular carcinoma cells, which undergo cell cycle arrest. According to the study, Kiyono speculated that higher and prolonged autophagy induction contributes to TGF-β mediated growth inhibition in hepatoma cells (Kiyono et al., 2009 ). Furthermore, Senturk et al. identified that the TGF-β as a major cytokine that is able to trigger a massive senescence response in HCC cell lines (Senturk et al., 2010) . Our findings demonstrated an increase in TGF-β1 levels and this cytokine is, possibly, capable of inducing senescence. The relationship between TGF-β, autophagy and senescence should be further investigated.
The pathways activation of PKA and/or PI3K/Akt/mTOR is the most important mechanisms of cell growth. Chang et al. showed that GLP-1 protects pancreatic beta cells from apoptosis in part through PKA and PI3K-dependent pathway (Chang et al., 2016) . Zhao et al., found that liraglutide inhibited Akt activation and that PI3K inhibitors displayed the same effects as liraglutide. Besides, prevented cancer cell migration and invasion, which lead them to conclude that GLP-1R activation by liraglutide plays an important role suppressing the cell growth (Zhao et al., 2014a) . The PI3K/Akt/mTOR pathway was associated with tumor growth and metastasis (Zhou and Huang, 2010) . The central mediator of the PI3K pathway is Akt which, once triggered, leads to mTOR activation, that regulates various cellular functions including cell metabolism and cell cycle progression. Consequently, hyperactivation of Akt and PI3K signaling pathway in a great number of human tumors has been related to advanced disease and poor prognosis (Zhou and Huang, 2010) . For this reason we have decided to evaluate the action of liraglutide on the PI3K/Akt/mTOR pathway. In this work, we observe that liraglutide, as well as rapamycin, is able to reverse the induction of insulin-induced growth. Knowing that rapamycin is a mTOR inhibitor and able to restrain the effects of insulin, we can suggest that both liraglutide and rapamycin acts by the same route of PI3K/Akt/mTOR and the anti-proliferative effect of liraglutide is possibly mediated by the inhibition of this pathway. 
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Conclusion
Our results show, for the first time, that liraglutide has antiproliferative effects via PI3K/Akt/mTOR, inducing autophagy and senescence in HepG2 cells. The increase of TGF-β1 is possibly related to senescence which explains the proliferation decrease. Because of that, liraglutide may have beneficial effect in hepatocellular carcinoma, being a promising candidate for future research.
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